TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Urokinase Therapy in Patients With Diabetic Foot Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetic patients with angiopathic or angioneuropathic diabetic foot syndrome and criticial limb ischemia~* No surgical or interventional treatment option~* No healing tendency of ulcerations despite of antibiosis and wound debridement after two-week treatment~* Fibrinogen \> 4.0 g/l~* No previous major amputation~Exclusion Criteria:~* Prior treatment of the current ulceration with urokinase~* Need for dialysis and/or creatinine-clearance \< 20ml/min~* INR \> 1,5 at screening~* Any kind of cerebral event within 3 months prior inclusion~* Proliferative retinopathy~* Uncontrolled hypertension~* Hemorraghic diathesis~* Gastrointestinal bleeding~* Pregnancy~* No compliance and/or participation in another trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Standard therapy (Type: OTHER): None
- B: Urokinase (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Placental Insufficiency Screening

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic hypertension under medication~* Insulin or not insulin dependant preexisting diabetes~* Previous history of pre-eclampsia~* Previous history of unexplained stillbirth~* Previous history of placental abruption~* Previous history of SGA (\< 10th centile)~* History of pre-eclampsia or chronic hypertension before 45 years in the mother or a sister~* History of vascular pathology before 50 years in the father~* Obesity (BMI\>26)~* Nulliparous after 38 years~* Assisted conception with donor~* Primipaternity after 38 years old or before 20 years old~Exclusion Criteria:~* Multiple pregnancy~* Pregnancy requiring termination~* Unability to understand the study~* Thrombophilia~* treatment with heparin

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dynaloc for Treatment of Femoral Neck Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men or women (see age specifications below) with subcapital femoral neck fractures (stable or unstable) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging (MRI).~* Patients between 50 and 69 years of age with any Garden type femoral neck fracture~* Patients older than 70 years of age with femoral neck fractures Garden type I and II~* Patients older than 70 years of age with a femoral neck fracture Garden types III and IV and contraindication to hemiarthroplasty.~* Operative treatment within 4 days (i.e., 72 hours) of presenting to the emergency room.~* Patient was ambulatory prior to fracture, though they may have used an aid such as a cane or a walker.~* Anticipated medical optimalization of the patient for operative fixation of the hip.~* Provision of informed consent by patient or proxy.~* Low energy fracture (defined as a fall from standing height).~* No other major trauma.~Exclusion Criteria:~* Associated major injuries of the lower extremity (i.e., ipsilateral or contralateral fractures of the foot, ankle, tibia, fibula, knee, or femur; dislocations of the ankle, knee, or hip; or femoral head defects or fracture).~* Retained hardware around the affected hip.~* Abnormal opposite hip making end-point evaluation impossible~* Infection around the hip (i.e., soft tissue or bone).~* Patients with disorders of bone metabolism other than osteoporosis (i.e., Paget's disease, renal osteodystrophy).~* Moderate or severe cognitively impaired patients (i.e., Six Item Screener with three or more errors).~* Patients with Parkinson's disease (or dementia or other neurological deficit) severe enough to increase the likelihood of falling or severe enough to compromise rehabilitation.~* Likely problems, in the judgment of the investigators, with maintaining follow-up. We will, for example, exclude patients with no fixed address, those who report a plan to move out of town in the next year, or intellectually challenged patients without adequate family support.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Cancellous screws (Type: ACTIVE_COMPARATOR): Patients in this group are having osteosynthesis with three screws
- Dynaloc (Type: ACTIVE_COMPARATOR): Patients in this group are having osteosynthesis with Dynaloc (three screws fixed in a small plate)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Mupirocin Decolonization on the Nasal Microbiome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: - Patients at VA-ECHCS who are starting a course of nasal mupirocin therapy for S. aureus decolonization~Exclusion Criteria:~Age \< 18 years Pregnant women Prisoners Decisionally challenged subjects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Staphylococcus aureus nasal carriers (Type: None): Patients who are treated with mupirocin to clear nasal colonization with Staphylococcus aureus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of IV/PO Acetaminophen in the Perioperative Period in Reducing Opiate Use After Lumbar Spine Fusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA (American Society of Anesthesiologists) I-III patients scheduled for elective one or two level minimally invasive lumbar fusions~Exclusion Criteria:~* Patients requiring surgery for neoplastic processes~* Allergy to acetaminophen~* Liver dysfunction and elevated Liver Function Tests (LFTs)~* Alcohol or drug dependency~* Mental retardation~* Less than 50 kg of weight~* regnant women~* Patients requiring long-acting opioid pain management (including fentanyl patch, oxycontin, etc) for over 3 weeks immediately prior to surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Acetaminophen IV Soln 10 MG/ML (A) (Type: EXPERIMENTAL): Patients in group A will receive 1 g of IV acetaminophen 15 minutes prior to wound incision, and every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
- PO acetaminophen (B) (Type: EXPERIMENTAL): Patients in group B will receive 1 g of PO acetaminophen prior to surgery, and 1 g of oral acetaminophen every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
- Hydromorphone (control arm) (C) (Type: ACTIVE_COMPARATOR): Patients in the control arm (Group C) will not receive acetaminophen for 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological confirmation of prostate adenocarcinoma~* Advanced prostate carcinoma.~* Previous treatment with hormones~* Levels of testosterone \< 50 ng/dL~* Good hematological, liver and kidney function~* Previous treatment with surgery or radiotherapy, at least 4 weeks since end of treatment is allowed (the patient should have been recovered from any side effects.~Exclusion Criteria:~* Previous chemotherapy (estramustine included).~* Second line hormonotherapy (oestrogens, gestagens, ketoconazole, ...included)~* Previous treatment with radiotherapy (isotopes) or previous radiotherapy over \> 25% of the marrow~* Any malignant process with a free disease interval under 5 years, exception done to non-melanoma skin cancer.~* Concomitant serious diseases~* Concomitant treatment with any other neoplassic therapy (exception done to LHRH agonists and/or biphosphonates).~* Contraindication for the treatment with estramustine.~* Previous history of pulmonary embolism, thromboembolic disease, previous treatment with anticoagulants (except aspirin), active thrombophlebitis or hypercoagulation.~* Previous history of pulmonary spillage or ascitis.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Docetaxel + Estramustine + Hydrocortisone
- 2 (Type: ACTIVE_COMPARATOR): Docetaxel + Prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mechanisms of Stroke in Intracranial Stenosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Enrolled in the medical arm of SAMMPRIS, signed consent~Exclusion Criteria:~* For QMRA testing: contraindications to MRI; for TCD testing, abscence of ultrasonographic windows.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced or metastatic pancreatic ductal adenocarcinoma, with at least one target lesion in the abdomen measuring \>= 1 cm~* The subject is able and willing to comply with study procedures and provide signed and dated informed consent~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent~* Patients unwilling or unable to undergo magnetic resonance (MR) imaging, including patients with contraindications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips~* Poorly controlled hypertension, defined as either systolic \> 170 or diastolic \> 110. The addition of anti-hypertensives to control blood pressure is allowed for eligibility determination~* Congestive heart failure \>= class III~* Myocardial infarction within the past year~* History of QT prolongation on electrocardiogram (EKG), defined as pretreatment QTs \> 440 msec in males or \> 460 msec in females~* Pregnant and lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A: Single Dose/Image (Type: EXPERIMENTAL): Patients receive hyperpolarized carbon C 13 pyruvate intravenously (IV) over less than one minute then undergo MRI over 5 minutes at baseline
- Cohort B: Multiple Dose/Images (Type: EXPERIMENTAL): Patients receive hyperpolarized carbon C 13 pyruvate IV over less than one minute then undergo MRI over 5 minutes at baseline and 4 weeks after beginning treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Outcomes With Merocel Packing or Thrombin-JMI for Anterior Epistaxis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking adults that have failed first line therapy for anterior epistaxis in the ER or the hospital~Exclusion Criteria:~* Non-english speaking patients~* Patients with bleeding disorders~* Known pregnant women or women that think they may be pregnant~* Patients with a know presence of antibodies to bovine thrombin preparations~* Patients that currently have or are known to have a history of systemic skin condition or rash such as eczema or psoriasis~* Patients found to have posterior epistaxis~* Patients requiring a surrogate for medical decisions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Thrombin-JMI
- 2 (Type: ACTIVE_COMPARATOR): Merocel pack

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with pathologically confirmed advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or has no standard therapy that improves survival by at least 3 months (unless temsirolimus is indicated as standard treatment for that disease).~2. Patients must have evaluable tumor(s) with documented PIK3 mutation and/or PTEN loss.~3. Patients must have creatinine \</= 3 X upper limit of normal (ULN); absolute neutrophil count \>/= 1,000/mL; platelets \>/= 50,000; bilirubin \</= 3.0 gm/dL. Except for patients with liver metastases: total bilirubin \</= 5 ULN.~4. Women of childbearing potential must have a negative baseline blood pregnancy test. Women and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study.~5. Patients must be off other anti-tumor agents for at least 5 half lives of the agent or 4 wks from the last day of treatment, whichever is shorter. For cytotoxic therapies, patients should be off treatment for 3 or more weeks.~6. Patients may not be receiving any other experimental agents that are not FDA approved.~7. Ability to understand and willingness to sign a written consent document.~8. Treatment on this study may begin within 24 hours after Phase 0 dose of Temsirolimus.~Exclusion Criteria:~1. Pregnant or lactating women.~2. Patients with creatinine clearance \<10 mL/min~3. Patients with a known hypersensitivity to any of the components or metabolites of the drug products.~4. Patients with major surgery within 30 days prior to entering study.~5. Patients on inhibitors or inducers of CYP3A4 metabolism will have the inhibitors or inducers stopped unless clinically contraindicated. See section 6 (Concomitant Medications) and Appendix E of the protocol for details.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temsirolimus (Type: EXPERIMENTAL): Temsirolimus 25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nebulized PL for Post-COVID-19 Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Voluntary signature of the IRB approved Informed Consent~2. At least 4-weeks post ventilator or oxygen dependent ARDS treated for at least 48 hours in the ICU~3. Patient is stable enough to have been discharged home~4. Male or female ages 18-85~5. Two weeks to 1-year post hospital discharge~6. Ongoing activity intolerance due to dyspnea related to ARDS~7. Is independent, ambulatory, and can comply with all post-operative evaluations and visits~8. 6-minute walk test distance of \< 450 M~9. SF-36 physical component score \< 60~10. ARDS caused by viral pneumonia including COVID-19 confirmed through an RNA anti-body test~11. Normal to mild post-ARDS reactive airway disease~Exclusion Criteria:~1. Oxygen dependent on nasal canula greater than 2-L per minute~2. Dependent on inhaled corticosteroid at the discretion of the physician~3. Unable to complete any of the outcomes measured (Spirometry, 6MWD, SF-36, etc.)~4. Active known secondary bacterial or viral infection~5. Active moderate or severe post-ARDS reactive airway disease at the discretion of the physician~6. Pre-morbid COPD~7. Medication list will be reviewed on a case by case basis to allow for flexibility as post-COVID-19 patients' medication list may vary~8. Other medical comorbidities/conditions that may preclude participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Platelet Lysate (Type: EXPERIMENTAL): Inhaled nebulized platelet lysate (PL), 2-ml 1x per day for 8 weeks.
- Saline (Type: ACTIVE_COMPARATOR): Inhaled nebulized normal sterile saline, 2-ml 1x per day for 8-weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Initial Safety Evaluation of FibroFix™ Meniscus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject (or guardian, if appropriate) has signed and dated a specific informed consent form~* The subject is over the age of 18~* The subject is able to comply with the protocol-defined preoperative procedures, the postoperative clinical and radiographic evaluations and the recommended rehabilitation regimen as determined by the investigator~* The subject has a diagnosis of an MRI or arthroscopically confirmed irreparable medial meniscus defect~* The meniscal defect should represent 25% or more of the meniscus and be amenable to repair~* The peripheral meniscal rim must be present~* The subject has a functionally intact anterior cruciate ligament~* Haemoglobin \>9g/dL and platelet count \>100,000/mm3 prior to Day 1~* No contraindication to general anaesthetic~* Female subjects of child-bearing potential: a negative urine pregnancy test~Exclusion Criteria:~* The subject has a functionally deficient anterior cruciate ligament~* The subject has concomitant posterior cruciate ligament insufficiency of the involved knee or a concomitant injury that interferes with the subject's ability to comply with the recommended rehabilitation program~* The subject has a diagnosis of untreatable Grade IV Outerbridge Scale degenerative cartilage disease in the involved knee joint~* Patients demonstrating an active local or systemic infection~* Any condition, which in the judgment of the Investigator would preclude adequate evaluation of the FibroFix™ Meniscus scaffold and clinical outcome.~* The subject has a history of confirmed anaphylactoid reaction~* The subject has received local administration of any type of corticosteroid or systemic administration of antineoplastic, immunostimulating, or immunosuppressive agents within 180 days prior to the scheduled surgery~* The subject has evidence of osteonecrosis of the involved knee~* The subject has a medical history that includes a confirmed diagnosis of rheumatoid or inflammatory arthritis, or relapsing polychondritis~* If female and of child-bearing potential: evidence of a positive pregnancy test or a stated intention to become pregnant in the next 6-12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FibroFix™ Meniscus scaffold (Type: EXPERIMENTAL): The test article for this study is the FibroFix™ Meniscus scaffold, which has been developed for repair of defects of the meniscus. It is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy